RANO工作组与EANO胶质瘤PET成像临床应用推荐更新
本政策综述由RANO PET工作组与欧洲神经肿瘤学会联合更新2016年指南,基于经组织分子学或临床病程验证的研究证据,推荐氨基酸PET优于葡萄糖PET用于胶质瘤鉴别诊断、分子信息预测、预后、活检引导、范围勾画及疗效评估,并提出PET RANO 1.0标准化疗效标准,同时指出缺乏PET改善患者结局的1级证据。
要点
- 推荐氨基酸PET优于葡萄糖PET用于胶质瘤临床管理。
- PET可用于鉴别诊断、分子信息预测、预后评估及活检引导。
- PET可用于勾画胶质瘤范围以规划手术和放疗。
核心结论
- 更新推荐基于经组织分子学或临床病程验证的研究证据,强调PET成像既往报道的临床价值及氨基酸PET优于葡萄糖PET。
- 指南强调缺乏显示将PET成像纳入临床流程可改善患者结局的1级证据,并指出未来临床研究应优先解决的空白领域。
研究设计与样本
- 本政策综述为RANO PET工作组与欧洲神经肿瘤学会的联合工作,是对2016年初始指南的更新。
- 推荐基于经组织分子学发现或临床病程验证PET发现的研究证据。
诊断标准与关键数值
- 提出基于PET的标准化疗效评估标准(PET RANO 1.0)用于治疗中患者的疗效评估。
- 推荐氨基酸PET优于葡萄糖PET用于胶质瘤患者的临床管理。
临床应用与阅片要点
- PET可用于胶质瘤患者的鉴别诊断、分子信息预测和预后评估。
- PET可用于活检引导及勾画胶质瘤范围以规划局部治疗(包括切除和放疗)。
- 治疗中患者可用PET评估对局部和全身治疗的疗效,并参照PET RANO 1.0标准。
局限性
- 指南强调缺乏显示将PET成像纳入临床流程可改善患者结局的1级证据。
- 指南指出未来需设计临床研究以解决上述证据空白。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
This Policy Review provides recommendations for the use of PET imaging in patients with gliomas and represents a joint effort of the Response Assessment in Neuro-Oncology (RANO) working group for PET and the European Association for Neuro-Oncology. The initial guideline was published in 2016, and summarised the previously established clinical benefit of PET with radiolabelled glucose and amino acid tracers in patients with gliomas. Since then, numerous additional studies have been published on this topic, focusing on differential diagnosis, prediction of molecular information, and prognostication. Further studies evaluated PET for biopsy guidance and delineation of glioma extent for local therapy planning, including resection and radiotherapy. In patients undergoing treatment, PET was studied for the assessment of response to local and systemic treatments and PET-based standardised response criteria (PET RANO 1.0) were proposed. In this Policy Review, the updated recommendations are based on evidence generated from studies that validated PET findings by histomolecular findings or clinical course. This guideline further underscores the previously reported clinical value of PET imaging and the superiority of amino acid PET over glucose PET, providing a framework for the use of PET in the management of patients with gliomas. The guideline also underscores the scarcity of class 1 evidence showing that incorporating PET imaging into clinical workflows improves patient outcomes, highlighting priority areas for future clinical studies designed to address this gap.
引用
- Galldiks N, Lohmann P, Aboian M, et al. Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas. Lancet Oncol. 2025. PMID: 40744043. doi:10.1016/S1470-2045(25)00193-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。